Number of Actions

No definition available.

Name:	pfe_NumberOfActions
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

+ Details

Name:	us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of judgment or settlement awarded to (against) the entity in respect of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The minimum amount the entity agreed to spend under the long-term purchase commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of damages awarded to the plaintiff in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusMylanPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_ProtonixPantoprazoleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_U.S.DepartmentofJusticeVersusPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ProductPricingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_EffexorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_TevaCanadaLimitedVersusPfizerCanadaInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_CelebrexandBextraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ProductSafetyMisrepresentationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Certain Matters Resolved And Purchase Commitments) (Details) CAD in Millions, $ in Millions			1 Months Ended			12 Months Ended				24 Months Ended
	Feb. 12, 2016 USD ($)	Jun. 30, 2014 CAD	Jul. 31, 2016 USD ($)	Oct. 31, 2014 Patents	Jun. 30, 2010 Patents	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2006 Patents	Dec. 31, 2012 CAD	Dec. 31, 2009 Actions
Loss Contingencies [Line Items]
Long-term purchase commitment, amount						$ 4,700.0
Sutent [Member] \| Pfizer Versus Mylan Pharmaceuticals Inc. [Member] \| Patent Infringement [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon \| Patents					3
Number of patents infringed upon \| Patents				2
Protonix / Pantoprazole [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)							$ (784.6)
Protonix / Pantoprazole [Member] \| U.S. Department of Justice Versus Pfizer [Member] \| Product Pricing [Member]
Loss Contingencies [Line Items]
Number of actions \| Actions											2
Litigation settlement income (loss)	$ (784.6)
Effexor [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss)								$ (56.0)
Effexor [Member] \| Teva Canada Limited Versus Pfizer Canada Inc. [Member] \| Pending Litigation [Member] \| Patent Infringement [Member]
Loss Contingencies [Line Items]
Litigation settlement income (loss) \| CAD										CAD (52.5)
Number of patents allegedly infringed \| Patents									1
Damages awarded \| CAD		CAD 125.0
Celebrex and Bextra [Member] \| Pending Litigation [Member] \| Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 486.0			$ 486.0